Prothena Corporation plc today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Affirm Holdings. Looking at options history for Affirm Holdings AFRM we detected 12 trades. If we consider the specifics ...

For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...

Mastercard and Affirm, though both in the digital payments arena, represent opposite ends of the spectrum—one a legacy ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Mastercard and Affirm are battling from opposite corners of the digital payments ring: one a legacy juggernaut, the other a fintech disruptor. Mastercard dominates with global infrastructure and ...

The jury’s verdict in this case is not excessive simply because it is in the amount of $725M,” Jacquinto wrote in response to ...

We recently compiled a list of the Traders Flee These 10 Stocks Today. In this article, we are going to take a look at where ...

Affirm Holdings, Inc.’s AFRM share price has dipped by 6.36%, which has investors questioning if this is right time to buy.

Dlocal (DLO) is putting pressure on fellow fintech stocks LendingClub (LC), Affirm (AFRM), and Robinhood (HOOD) ...

J.P. Morgan analysts stepped away from a recent conference with reinvigorated confidence in Affirm Holdings. In their view, ...